Brief Communication: Tamoxifen Therapy for Nonmalignant Retroperitoneal Fibrosis

  title={Brief Communication: Tamoxifen Therapy for Nonmalignant Retroperitoneal Fibrosis},
  author={Eric F.H. van Bommel and Tadek R. Hendriksz and A W Huiskes and A G Zeegers},
  journal={Annals of Internal Medicine},
Context There are few effective treatments for retroperitoneal fibrosis. Contribution Of 19 adults with nonmalignant retroperitoneal fibrosis treated with tamoxifen for variable durations of time, 15 reported substantial resolution of symptoms and 14 had computed tomography scans that showed slow regression of retroperitoneal masses. Three men reported minor losses of libido, and 1 patient developed reversible hepatitis. Caution There was no control group in this small observational study… 

Tamoxifen Monotherapy in the Treatment of Retroperitoneal Fibrosis

Tamoxifen is an alternative in the medical treatment of RPF, especially if patients want to avoid glucocorticoids and the potential of regression of fibrosis seems to be slightly inferior and the relapse rate is higher compared to steroids, but the rate of successful DJ removals is comparable.

Outcome in patients with idiopathic retroperitoneal fibrosis treated with corticosteroid or tamoxifen monotherapy

CS are superior to TMX in treating iRPF disease, however, in patients with initial treatment success with primary treatment, recurrence rate was lower in TMX-treated patients.

Medical management of retroperitoneal fibrosis.

Combined prednisone and mycophenolate mofetil appears to be an effective therapeutic option for patients with retroperitoneal fibrosis.

Long-term renal and patient outcome in idiopathic retroperitoneal fibrosis treated with prednisone.

One-year treatment with prednisone is associated with a high rate of initial success, but a high recurrence rate, and despite frequent disease relapse, long-term renal and patient outcome was good.

Combined Prednisone and Mycophenolate Mofetil Treatment for Retroperitoneal Fibrosis

Combined prednisone and mycophenolate mofetil therapy is a potentially effective treatment for retroperitoneal fibrosis that warrants evaluation in randomized trials.

Retroperitoneal fibrosis after chemo‐radiotherapy for cervical cancer: A case report

The case of a 47‐year‐old woman who complained of lower abdominal pain 14 months after chemo‐radiotherapy for cervical cancer and was diagnosed with RPF caused by radiotherapy, which is doing well with no recurrence to date is reported.

Treatment of idiopathic retroperitoneal fibrosis with colchicine and steroids: a case series.

Colchicine in association with a low induction dose of steroids produced remission rates in patients with IRPF similar to those for regimens using greater steroid doses alone or in combination with immunosuppressive drugs, and may have contributed to recurrence prevention.

Management of idiopathic retroperitoneal fibrosis from the urologist’s perspective

The imaging procedures available today are unable to accurately differentiate between idiopathic and malignant RF and more clinical studies are needed in order standardize the protocol for diagnostic, treatment and follow up after medical or surgical management.



Treatment of retroperitoneal fibrosis with tamoxifen: case report and review of literature.

Tamoxifen represents an attractive and safe choice of medical treatment for retroperitonea fibrosis, particularly in the acute stages, and the duration of treatment, the effectiveness and the persistence of the results are still uncertain because few cases have been reported in the literature.

Steroid therapy for idiopathic retroperitoneal fibrosis: dose and duration.

Retroperitoneal fibrosis treated with tamoxifen.

Tamoxifen has been shown to be effective in the treatment of desmoid tumors, and a patient with retroperitoneal fibrosis who was treated successfully with this anti-estrogen may be a useful treatment in this disease.

The response of retroperitoneal fibrosis to tamoxifen.

Tamoxifen is effective in the treatment of desmoid tumors, and it is reported its use in two patients with retroperitoneal fibrosis with excellent results.

Retroperitoneal fibrosis treated with methylprednisolon pulse and disease-modifying antirheumatic drugs.

This report describes 11 cases of RF with ureteric obstruction treated with methyl-prednisolon pulse therapy in combination with azathioprine or penicillamine following initial insertion of Ureteral stents, a principle of non-operative management of RF.

[Retroperitoneal fibrosis].

A 53-year-old man without previous significant illness developed severe backache and the marked urinary obstruction necessitated the implantation of double-J-stents, which led to idiopathic retroperitoneal fibrosis being diagnosed.

Remission of Idiopathic Retroperitoneal Fibrosis after Sequential Therapy with Corticosteroids and Tamoxifen

A case of idiopathic retroperitoneal fibrosis treated successfully with intra peritonealization of the ureters and sequential therapy with steroids and tamoxifen to minimize the side effects is presented.

Tamoxifen for retroperitoneal fibrosis.

A case of a woman with retroperitoneal fibrosis associated with aortic inflammatory aneurysm, who was successfully treated with oral tamoxifen is reported.

Computed tomography in the follow-up of retroperitoneal fibrosis.

Gallium-67 imaging in retroperitoneal fibrosis: significance of a negative result.

  • A. Jacobson
  • Medicine
    Journal of nuclear medicine : official publication, Society of Nuclear Medicine
  • 1991
In patients with multiple retroperitoneal and/or mediastinal masses, gallium imaging may be useful in identifying the most active sites of disease for possible biopsy and for subsequent monitoring of response to therapy.